Figure 4.

Activation of Keap1-Nrf2 pathway in HepG2 cells. (A) Representative western blots and (B) quantification of Nrf2 in nuclear (nuc) and cytoplasmic (cyto) fraction of HepG2 cells after 24 h-treatment with 10 and 20 µM lapatinib (Lap). Lamin B1 (nuclear fraction) and GAPDH (cytoplasmic fraction) represent the loading controls. (C) mRNA expression of the Nrf2-regulated genes Nqo1 and Gsta1 in HepG2 cells after treatment with 2–20 µM lapatinib (Lap) for 24 h. Data are shown as fold increase relative to the negative control (0.1% DMSO, Ctrl), and are the mean ± SEM of at least three independent replicates. ^*p < 0.05 versus negative control, ^#p < 0.05 versus the same concentration of lapatinib of the other experimental group.